CAJ | 학술논문

目的观察地尔硫(卓)对冠心病患者经皮冠状动脉介入治疗(PCI)术后6个月内主要不良心血管事件(MACE)的影响. 方法冠心病PCI术后的患者192例,随机分为地尔硫(卓)治疗组(治疗组)101例和常规治疗组(对照组)91例,观察两组患者术前、术后24 h超敏C反应蛋白(hsCRP)的变化水平及6个月内MACE的发生. 结果治疗组和对照组患者PCI术后hs-CRP分别为(6.59±1.45)mg/L、(8.37±1.82)mg/L,较术前(4.11±0.82) mg/L、(4.25±0.67) mg/L明显升高(t=14.962、20.265,均P=0.000),但与对照组比较,治疗组术后hs-CRP升高幅度较低(t=7.529,P=0.000);治疗组6个月内MACE的发生人数为9例,较对照组23例低,差异有统计学意义(x2 =9.229,P=0.002). 结论 PCI术后予以地尔硫(卓)治疗能降低6个月内MACE的发生.
목적 관찰지이류(탁)대관심병환자경피관상동맥개입치료(PCI)술후6개월내주요불양심혈관사건(MACE)적영향. 방법 관심병PCI술후적환자192례,수궤분위지이류(탁)치료조(치료조)101례화상규치료조(대조조)91례,관찰량조환자술전、술후24 h초민C반응단백(hsCRP)적변화수평급6개월내MACE적발생. 결과 치료조화대조조환자PCI술후hs-CRP분별위(6.59±1.45)mg/L、(8.37±1.82)mg/L,교술전(4.11±0.82) mg/L、(4.25±0.67) mg/L명현승고(t=14.962、20.265,균P=0.000),단여대조조비교,치료조술후hs-CRP승고폭도교저(t=7.529,P=0.000);치료조6개월내MACE적발생인수위9례,교대조조23례저,차이유통계학의의(x2 =9.229,P=0.002). 결론 PCI술후여이지이류(탁)치료능강저6개월내MACE적발생.
Objective To detect the impact of Diltiazem on the major adverse cardiac events (MACE) in six months after percutaneous coronary intervention (PCI).Methods A total of 192 patients after PCI with coronary atherosclerotic heart disease were enrolled in this study.The patients were randomly divided into Diltiazem therapy group (101 patients) and non-Diltiazem therapy group (91 patients).The high-sensitivity C-reactive protein (hs-CRP) was assessed before and 24 h after PCI,and the incidence of Major adverse cardiovascular events(MACEs) were assessed at the sixth month after PCI.Results Compared with before PCI,hs-CRP level increased significantly in both group after PCI (P＜0.01),but hs-CRP level was lower in Diltiazem therapy group than in non-Diltiazem therapy group (P＜0.05).Compared with non-Diltiazem therapy group,there was lower incidence of MACEs during six months follow-up in Diltiazem therapy group.Conclusions Diltiazem can decrease the incidence of MACEs during six months after PCI.